Definium Therapeutics (DFTX) EBT (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly EBT of -$58.2 billion for Q1 2026, down 191821.42% year-over-year from N/an in Q1 2025, and down 128642.85% quarter-over-quarter from -$45.2 million in Q4 2025.
Definium Therapeutics (DFTX) EBT (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported EBT for 6 consecutive years, with -$58.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 191821.42% year-over-year to -$58.2 billion; the TTM figure through Mar 2026 stood at -$60.9 billion (down 58428.33% YoY), while the FY2025 annual figure was -$31.1 billion, down 632.56% from the prior year.
- EBT declined to -$58.2 billion in Q1 2026 per DFTX's latest filing, from -$45.2 million in the prior quarter.
- Across five years, EBT topped out at -$4.9 million in Q4 2022 and bottomed at -$58.2 billion in Q1 2026.
- Historically, EBT has averaged -$3.6 billion across 5 years, with a median of -$22.0 million in 2024.
- Annual changes were most pronounced in 2022 — EBT surged 62.53% — and 2026, when it slumped 191821.42%.
- Definium Therapeutics' EBT stood at -$4.9 million in 2022, then tumbled by 342.2% to -$21.7 million in 2023, then tumbled by 37.63% to -$29.8 million in 2024, then sank by 51.52% to -$45.2 million in 2025, then sank by 128642.85% to -$58.2 billion in 2026.
- Business Quant data shows DFTX's EBT at -$58.2 billion in Q1 2026, -$45.2 million in Q4 2025, and -$44.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | -306.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -306.36 Mn |
| Mar 31, 2026 | -58.21 Bn |
| Dec 31, 2025 | -45.21 Mn |
| Sep 30, 2025 | -44.71 Mn |
| Jun 30, 2025 | -2.57 Bn |
| Mar 31, 2025 | -30.33 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -20.98 Mn |
| Dec 31, 2023 | -21.68 Mn |
| Sep 30, 2023 | -21.06 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -27.99 Mn |
| Dec 31, 2021 | 26.59 Mn |
| Sep 30, 2021 | -17.20 Mn |